Immunotherapy utilization in stage IIIA melanoma: less may be more.

Front Oncol · 2024 · PMC10876869 · PMID 38380358

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Another recent real-world study of 183 patients with stage IIIA melanoma using the Flatiron database identified a trend towards longer overall survival in those receiving adjuvant nivolumab, but this trend did not reach statistical significance ( 30 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.